JAMA Surgery, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 25, 2024
Language: Английский
Medicina, Journal Year: 2024, Volume and Issue: 60(6), P. 1010 - 1010
Published: June 20, 2024
Hepatocellular carcinoma is the most common primary liver tumor. Orthotopic transplant one of best treatment options, but its waiting list has to be considered. Bridge therapies have been introduced in order limit this issue. The aim study evaluate if bridge advanced hepatocellular can improve overall survival and reduce de-listing. We selected 185 articles. search was limited English articles involving only adult patients. These were deduplicated with incomplete text or irrelevant conclusions excluded. Sorafenib standard care for increases without any significant drug toxicity. However, benefit limited. combination transarterial chemoembolization + sorafenib, instead, delays tumor progression, although still uncertain. A few studies shown that patients undergoing radiation therapy similar even better outcomes than those sorafenib alone rates histopathologic complete response (89% had no residual explant). Also, combined radiotherapy compared association associated a rate (24 vs. 17 months). Moreover, immunotherapy revealed new encouraging perspectives. Combination showed results could become gold as carcinoma.
Language: Английский
Citations
0
International Journal of Surgery Open, Journal Year: 2024, Volume and Issue: 62(4), P. 501 - 502
Published: May 24, 2024
Language: Английский
Citations
0
JAMA Surgery, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 25, 2024
Language: Английский
Citations
0
JAMA Surgery, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 25, 2024
Language: Английский
Citations
0